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Transmissible spongiform encephalopathies „TSEs… are lethal infectious
neurodegenerative diseases. TSEs are caused by prions, infectious agents
lacking informational nucleic acids, and possibly identical with higher-order
aggregates of the cellular glycolipoprotein PrPC. Prion strains are derived from
TSE isolates that, even after inoculation into genetically identical hosts, cause
disease with distinct patterns of protein aggregate deposition, incubation times,
morphology of the characteristic brain damage, and cellular tropism. Most of
these traits are relatively stable across serial passages. Here we review current
techniques for studying prion strain differences in vivo and in cells, and discuss
the strain phenomena in the general context of the knowledge gained from




Prion diseases or transmissible
spongiform encephalopathies are
neurodegenerative diseases that are, in
most cases, infectious and invariably
fatal. Similarly to other protein mis-
folding disease of the central nervous
system, prion diseases manifest them-
selves through strong neurological
signs, including rapidly progressive
dementia, ataxia, and variable loss of
brain function depending on the prion
disease. Most reported human cases
are sporadic in origin (sCJD), i.e.,
caused by unknown factors, less
than 10% of the remaining cases are
familial Creutzfeldt–Jakob disease,
Gerstmann–Sträussler–Scheinker syn-
drome, or fatal familial insomnia
(Glatzel et al., 2003; Collins et al.,
2004). Familial forms of prion diseases
have all been linked to mutations in the
gene encoding for the cellular prion
protein PrPC, termed Prnp (Hsiao and
Prusiner, 1990). Prions can also effi-
ciently be transmitted from one indi-
vidual to another and even across ani-
mal species. Known cases involve
transmission from human to human
through ritual cannibalism (Kuru),
through contaminated medical prod-
ucts and blood (iatrogenic CJD) and
from cattle to humans, known as vari-
ant CJD (Gajdusek et al., 1966; Col-
linge, 2001; Llewelyn et al., 2004;
Wroe et al., 2006). Major neuropatho-
logical hallmarks of transmissible
spongiform encephalopathies (TSEs)
are extensive spongiosis, neuronal cell
loss in the central nervous system, glio-
sis (DeArmond, 1993), and deposition
of amyloid plaques or amorphous PrP
aggregates (Bendheim et al., 1984;
DeArmond et al., 1985).
PRION REPLICATION
The idea that a protein lacking any ge-
netic material could operate as an in-
fectious agent was first proposed by
Griffith on the basis of experiments
showing an unusually high level of re-
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sistance of the infectious agent (later termed the prion agent)
to ultraviolet irradiation, high temperature, and other aggres-
sive physical conditions, suggesting the absence of nucleic
acid (Griffith, 1967). But it was the purification and the bio-
chemical characterization of PrPSc, a protein form only
found in scrapie infected animals, that led to the formulation
of the “protein-only” hypothesis by Stanley Prusiner (Bolton
et al., 1982). Charles Weissmann and Bruce Chesebro then
independently discovered that PrPSc was encoded by the
Prnp gene, a gene also encoding for the normal cellular pro-
tein PrPC, the physiological function of which remains un-
known (Chesebro et al., 1985; Oesch et al., 1985). The
protein-only hypothesis, the prevailing hypothesis on the na-
ture of the infectious prion, proposes that the infectious dis-
ease causing agent consists essentially of PrPSc, an abnor-
mally folded, protease resistant, -sheet rich isoform of the
normal cellular prion protein, denoted PrPC (Prusiner, 1991).
No known covalent modifications have been found to differ-
entiate the two proteins PrPC and PrPSc (Stahl et al., 1993). It
was therefore proposed that PrPSc is a posttranslational de-
rivative of PrPC having acquired a different three-
dimensional conformational structure and that pathological
PrPSc acts as a template to convert more PrPC. The prion
concept was further refined by Weissmann (1991) to denote
an infectious protein that does not contain any coding nucleic
acids and the infectivity of which propagates by recruitment
and “autocatalytic” conformational conversion of cellular
prion protein into disease-associated PrPSc (Aguzzi et al.,
2007). The current prevalent model is that it is not mono-
meric PrPSc that is responsible for the conversion of PrPC,
but rather oligomeric species bearing a certain range of sto-
ichiometries (Silveira et al., 2005). It is thought that PrPSc
can form higher order aggregates that can act as a nucleation
site for the growth of PrPSc fibrils. Here, the hypothesis is
that the ends of these fibrils recruit PrPC or PrPSc monomers
and stabilize the PrPSc conformation through incorporation
into the growing fibril (Aguzzi et al., 2007).
The physiological function of PrPC is not well under-
stood. PrPC has been linked to neuronal signal transduction,
lymphocyte function, copper-binding, as well as pro- and
antiapoptotic functions (Aguzzi and Polymenidou, 2004).
Mice devoid of PrPC show only a mild phenotype, indicating
that prion diseases are not caused by a loss-of-function
(Büeler et al., 1992). Indeed the most compelling evidence
in favor of the protein only theory is that PrP-null mice are
completely resistant to experimental transmission of prions,
showing that PrPC is crucial for prion replication (Büeler
et al., 1993). Furthermore, it was found that de novo prion
infectivity can be generated, albeit inefficiently, by in vitro
fibrillization or by sonicating a mixture of purified lipids,
synthetic polyanions, and native PrPC purified from normal
hamster brain (Legname et al., 2004; Deleault et al., 2007).
The prion phenomenon exists also in non-mammalian
eukaryotes such as yeast. Fungal prions are non-PrP re-
lated molecules, including HET-s, Ure2p, Sup35 proteins,
that show prion properties in that they can adopt both non-
amyloid and self-perpetuating amyloid structures. The con-
version of these molecules has been shown to have important
physiological functions. Conversion of Ure2p and Sup35
into their amyloid forms (URE3 and PSI+, respectively)
regulates transcription and translation of specific yeast genes
(Tanaka et al., 2006; Immel et al., 2007). HET-s in its amy-
loid form regulates heterokaryon incompatibility, a fungal
self/nonself-recognition phenomenon that prevents different
forms of parasitism (Wasmer et al., 2008). So far there have
been few examples of mammalian protein that are function-
ally, in a nonpathological way, regulated by interconversion
between amyloid and nonamyloid forms. A remarkable ex-
ample is the synthesis of melanine which has been shown to
involve amyloid structures (Fowler et al., 2007). In addition,
it has been proposed that proteins involved in establishing
long-term memory might do so by converting reversibly to
and from a prion-like state (Si et al., 2003; Shorter and
Lindquist, 2005).
PRION STRAINS
In its most basic form, the seeding hypothesis is likely to rep-
resent an oversimplification, as it has been known for over
40 years that different prion strains can be isolated from the
same species (Pattison and Millson, 1961). Prion strains are
defined as infectious isolates that, when transmitted to iden-
tical hosts, exhibit distinct prion disease phenotypic traits.
The main traits used to distinguish strains in vivo were his-
torically based on the incubation time, which is the period it
takes from the time point of an experimental inoculation to
onset of clinical disease (Bessen and Marsh, 1992b). Other
traits commonly used to differentiate strains include histo-
pathological lesion profiling, i.e., the distribution and char-
acteristics of PrPSc deposits and the degree of vacuolization
in nine different specific brain regions, as well as clinical
signs (Fraser and Dickinson, 1973; Bruce, 1993; Fraser,
1993; Sigurdson et al., 2007). Phenotypic traits are mostly
stable upon serial transmission (the continued passaging of
infectious brain homogenate from a sick mouse into a
healthy one), unless having been transmitted over a species
barrier.
When prion isolates obtained from one species are trans-
mitted experimentally into an animal of another species,
often a characteristic delay in the onset of clinical disease
is observed upon first passage, which is referred to as a
species barrier. This incubation time is typically significantly
reduced upon a second round of serial transmission into
the same host-species, a phenomenon termed “adaptation”
(Kimberlin et al., 1987; Sigurdson et al., 2007). The species
barrier is thought to result from incompatibilities between
the preferred host PrP structure in the fibrillary state and the
specific conformation of PrP present in the inoculum. The
species barrier can be unidirectional in that it inhibits the
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transmission of the mouse-adapted scrapie strain 139A into
rat, but not rat-adapted 139A into mice (Kimberlin et al.,
1987). Alternatively, it can be bidirectional, or in some in-
stances it may not exist at all (Kimberlin et al., 1987). Often
new distinct strains can be observed upon transmission of
prions across an interspecies barrier or into animals of the
same species expressing different polymorphisms in the
prion gene, a phenomenon sometimes referred to as a “strain
mutation” (Bruce, 1993; Wadsworth et al., 2004). New
strains can arise upon cross-species barrier transmission
even if the strains have been previously “cloned” (Kimberlin
et al., 1989). The latter procedure consists of selecting single
prions by limiting endpoint dilution into mice, such as only
one prion species should arise from an individual host
(Bruce and Dickinson, 1987; Bruce, 1993). Therefore, it
is not clear if one can indeed “clone” out a prion strain.
Potentially, multiple strains exist in a cloned homogenate
prior to transmission out of which one strain can become
the dominant species depending on selection for the strain
most congruent with the host PrP molecule. This interpreta-
tion is analogous to the quasispecies theory of RNA viruses
(Biebricher and Eigen, 2006). Alternatively, new strains
might be generated de novo due to strain “mutations” of un-
known etiology (Weissmann, 1991). It is clear that in some
patients suffering from CJD, multiple distinct types of CJD-
associated PrPSc molecules coexist within the same patient,
speaking in favor of the first hypothesis (Polymenidou et al.,
2005).
STRAIN DISCRIMINATION
Strain-specific properties of prions could hypothetically be
encoded by an ancillary genome consisting, e.g., of RNA
species, or even of microRNA. Although anionic polymers
including RNA species appear to facilitate prion conversion
in vitro, no clear evidence in favor of the notion that nucleic
acids determine the characteristics of prion strains has been
forthcoming (Weissmann, 1991; Deleault et al., 2003). Alter-
natively, PrPSc might possess several different disease-
associated strain conformations, all of which can cause and
transmit disease, with specific disease phenotypes being de-
termined by specific conformations or aggregation number
of PrPSc in the donor inoculum. Speaking in favor of this hy-
pothesis, several different lines of circumstantial evidence
seem to support that there are unique biochemical and bio-
physical characteristics of individual prion strains.
The most commonly used methods to biochemically
describe prion strains are based on differences in electro-
phoretic mobility after proteinase K digestion and glyco-
sylation patterns (the ratio between un-, mono-, and
diglycosylated PrP) (Bessen and Marsh, 1992a; Collinge
et al., 1996; Parchi et al., 1996; Khalili-Shirazi et al., 2005).
Sedimentation coefficients and the extent of PK resistance
either in the absence (Bessen and Marsh, 1992a) or presence
of different concentrations of chaotropic salt are strain de-
pendent, which suggest that different strains aggregate to a
different extent and/or that they vary in their tertiary or qua-
ternary fold and inherent stability to unfolding (Peretz et al.,
1997; Safar et al., 1998). This notion is supported by the
fact that certain antibody epitopes are buried within the
globular protein domain of the prion protein to a different
extent upon conversion. These buried epitopes can be ex-
posed by chaotropic salts and the ratio of available to buried
epitopes can be used to distinguish unique strains, the so-
called conformation dependent immunoassay (Safar et al.,
1998).
The different lesion profiles seen in the brains of mice
infected with different prion strain isolates suggest that sta-
bility and conformation of PrPSc are not the only differences
between strains (Tremblay et al., 2004). It appears that there
is a disparity between the cell tropism of various strains. In-
deed it can be shown that prion strains upon intraperitoneal
inoculation replicate in the spleen to a variable extent prior to
entry into the CNS (Aguzzi and Sigurdson, 2004). Recently,
the phenomenon of cellular prion tropism was clearly illus-
trated by the work of Weissmann’s group who could show
that a panel of cell lines would replicate prion strains to dif-
fering degrees. All of the cell lines were fully capable of sup-
porting prion replication by the mouse-adapted scrapie strain
22L, but only one cell line, the CAD5 cell line, would sup-
port the replication of mouse-adapted BSE strain 301C. And
whereas CAD5 cells would replicate all strains, R33 cells
would only replicate the 22L strain and not 301C, RML, and
Me7 (Mahal et al., 2007). This study clearly illustrates that at
present we lack the full knowledge of what a prion strain is.
The differential cell tropism of the various prion strains
clearly implies the requirement for cell-specific cofactors, be
it chaperones, specific uptake receptors, RNA species, a par-
ticular lipid environment, a specific post-translationally
modified PrP molecule, or a particular prion replicating sub-
cellular environment. Currently, there is no consensus on the
nature of this cofactor, but much work in different groups is
currently focused on identifying the type of cofactors impli-
cated in prion growth in living systems.
STRAINS AND SMALL MOLECULE DYES
Most detection methods for distinguishing individual prion
strains rely on biochemical techniques applied to homoge-
nates of prion-containing samples or transmission studies,
neglecting the aspect of spatial distribution of prions. The
presence of histologically visible -sheet rich protein aggre-
gates, called amyloid deposits, can be visualized by small
amyloidotropic dyes, such as derivatives of Congo red, and
thioflavins (Nilsson, 2004). These dyes bind with various de-
grees of selectivity to protein aggregates that display exten-
sive cross -pleated sheet conformations with a high degree
of structural symmetry. Hence, the presence of mature amy-
loid deposits is detected by these dyes as enhanced fluores-
cence (thioflavins) or apple-green birefringence under cross
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polarized light (Congo red). Congo red, an aromatic sul-
fonated azo dye, was introduced more than 80 years ago
and its gold-green birefringence under polarized light has
been the gold standard for amyloid detection ever since
(Bennhold, 1922; Divry, 1927). However, these dyes are not
suitable for recognizing “prefibrillary” species (which are
often, by way of a circular argument, defined as non-
congophilic amyloids). Also, amyloid deposits of diverse
morphological origin, such as prion strains, cannot be
separated.
In order to address these limitations, luminescent conju-
gated polymers (LCPs) were recently developed as a novel
class of amyloidotropic dyes (Herland et al., 2005; Nilsson
et al., 2005; 2006). These dyes contain a swiveling thiophene
backbone and the optical processes, e.g., the fluorescence
from the dye, are highly sensitive to the geometry of the
thiophene backbone. Upon interaction with protein aggre-
gates of distinct morphologies, the rotational freedom of the
LCP backbone is restricted in specific ways, disrupting the
conjugation of the  electron systems within the poly-
thiophene chains. This generates optical fingerprints that are
often unique to given protein conformations. Instead of
simply measuring the total amount of aggregated protein,
heterogeneous populations of specific protein aggregates
can be differentiated by LCP staining. This phenomenon was
recently observed in a transgenic mouse model with AD
pathology, where a striking heterogeneity in the characteris-
tic plaques composed of the beta-amyloid peptide A was
identified with the LCPs (Nilsson et al., 2007). LCP staining
of brain tissue slices revealed different subpopulations of
plaques, seen as plaques with different colors. The spectral
features of LCPs enabled an indirect mapping of the plaque
architecture, as the different colors of the LCPs are associ-
ated with different conformations of the thiophene back-
bone. Further evidence for the idea that the prion strain
phenomenon is encoded in the structure of the prion ag-
gregates is provided from the analysis of brain sections
stained by LCPs from mice infected with distinct prion
strains (Sigurdson et al., 2007). The LCPs not only bound
specifically to the prion deposits, even those which were
negative for other amyloidotropic dyes (Congo red and ThT),
but also different prion strains could be separated due to
individual staining patterns of LCPs with distinct ionic
sidechains. Furthermore, the anionic LCP, PTAA, emits
light of different wavelengths when bound to distinct pro-
tein deposits associated with a specific prion strain
[Figs. 1(a)–1(c)]. As the emission profiles of LCPs are asso-
ciated with geometrical changes of the LCP backbone, ratios
of the intensity of the emitted light at certain wavelengths
can be used as an indicator of the geometry of the LCP
chains (Berggren, 1999; Nilsson et al., 2002). For example,
nonplanar and separated LCPs chains emit light around
530–540 nm, whereas a planarization of the thiophene back-
bone will shift the emission maximum (Emax) towards
longer wavelengths. A planar backbone might also give rise
to an aggregation of LCP chains, seen as an increase of the
intrinsic emission around 640 nm. When plotting the ratio
532/Emax and the ratio 532/639 nm in a correlation dia-
gram, prion aggregates associated with distinct prion strains,
mouse-adapted chronic wasting disease (mCWD), mouse-
adapted sheep scrapie (mSS), and mouse-adapted BSE were
easily distinguished from each other, illustrating the useful-
ness of spectral properties of LCPs for the classification of
protein deposits [Fig. 1(d)]. These conformation dependent
spectral characteristics can only be afforded by LCPs and
provide the opportunity to acquire optical fingerprints for
protein aggregates which correlates with distinct prion
strains.
Although it was shown that the emission profile of LCPs
could be used to characterize protein deposits, further evi-
dence was necessary to enable relating the geometrical alter-
ations of the LCPs to a structural variance of the protein de-
posits associated with the distinct prion strains. By taking
recombinant mouse prion protein (mPrP) and converting it
into two different types of amyloid fibrils by using varying
conditions for fibrillation, Sigurdson et al. were able to show
that the emission profile of PTAA could be used to distin-
guish the two fibril preparations [Fig. 1(e)] (Sigurdson et al.,
2007). As these two preparations of fibrils were chemically
identical, having the same protein (mPrP) and being dialyzed
Figure 1. Prion strain discrimination by LCPs. a Chemical
structure of the anionic LCP, PTAA. b–c Fluorescence images
showing PTAA bound to PrP aggregates from mCWD b and mSS
c. Typical PTAA stained aggregates are seen in yellow-red and are
indicated with white arrows. Scale bars represent 50 m. d Corre-
lation diagram of the ratios of emitted intensities, R532/639 and
R532/Emax, of the intensity of the emitted light from PTAA bound to
PrP plaques in individual cases of mCWD and mSS. Each symbol
represents the mean value from 3–5 different plaques within a single
mouse. For mCWD or mSS, data was collected from four or two
different passages, respectively. e Emission spectra of PTAA
bound to native or fibrillar recombinant mouse PrP. RFU, relative
fluorescence units.
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against the same buffer, the spectral differences seen for
PTAA were most likely due to structural differences between
the fibrils. Hence, LCPs provide indirect structural insights
into the morphology of individual prion aggregates and can
be used as a complementary technique to conventional stain-
ing protocols for the characterization of protein deposits as-
sociated with individual prion strains. However, further stud-
ies of complexes between in vitro produced prion aggregates
with defined conformations and LCPs with distinct ionic
sidechain functionalities or different chain lengths will likely
be necessary in order to understand the origin of the correla-
tion of the spectroscopic readout from the LCP and the mo-
lecular structure of the prion aggregate. Although the
achievement of obtaining certain spectroscopic LCP signa-
tures from protein aggregates associated with distinct prion
strains are beneficial compared to conventional amyloido-
trophic dyes, correlating this spectroscopic signature to a
specific form of the aggregated protein is still necessary in
order to gain novel insight into the pathological process of
the disease. Nevertheless, the LCPs can be useful for com-
parison of heterogeneous prion aggregates in well-defined
experimental systems and offers a novel tool to study prion
strain adaptation and competition between distinct prion
strains.
ELEMENTARY STEPS OF PRION PROPAGATION
The physical basis for the propagation of prions constitutes a
key element in refining our fundamental understanding of
their biological activity. It is increasingly apparent that many
aspects of prion behavior such as the species barrier for their
transmission and the existence and stable propagation of
multiple prion strains can be rationalized based on a finite set
of kinetic and structural conditions on the elementary steps
which underlie prion growth. In agreement with this idea, the
fact that the strain phenomena is ubiquitous in prion biology,
being found for mammalian prions (Safar et al., 1998; Jones
and Surewicz, 2005; Sigurdson et al., 2007) as well as for
naturally occurring and artificial fungal prions (Glover et al.,
1997; Chien and Weissman, 2001; DePace and Weissman,
2002), strongly suggests that it arises from common physical
determinants rather than from specific sequence dependent
effects—an intriguing manifestation of universality within a
complex biological setting. The aim of this section is to give
a brief overview of recent progress towards understanding
the physical principles which govern prion growth and to dis-
cuss some of the implications of such theories for the biology
of these systems.
The realization that certain types of natural epigenetic in-
formation transfer processes in fungal species are mediated
by prion forms of endogenous proteins has provided an ex-
perimentally tractable framework for the detailed study of
mechanisms associated with prion propagation. In many
cases the current level of biophysical information available
for prions in fungi is more detailed than for mammalian pri-
ons. Strong analogies and similarities, some discussed be-
low, are, however, emerging and many of the findings for
yeast prions have parallels in mammalian prion biology and
in some cases even in the wider class of noninfectious self-
propagating -sheet rich amyloid fibrils.
The process by which proteins convert from their normal
soluble state into the prion form according to the protein only
mechanism (Prusiner, 1982; King and Diaz-Avalos, 2004;
Tanaka et al., 2004) can conceptually be separated into two
steps (Collins et al., 2004), namely: (1) the conformational
rearrangement using the end of an existing prion aggregate
as a template to misfold the protein monomer and enable its
incorporation into the growing fibril; and (2) the multiplica-
tion of prions through fragmentation of existing structures
(Fig. 2). This mechanism has been experimentally verified
for yeast prions (Collins et al., 2004; King and Diaz-Avalos,
2004; Tanaka et al., 2004; Brachmann et al., 2005). There are
indications that similar processes govern the growth of mam-
malian prions (Legname et al., 2004; Castilla et al., 2005;
Legname et al., 2005; Weber, 2006) and indeed also of non-
prion related amyloid fibrils (Dobson, 2003). In addition, for
many amyloid systems spontaneous nucleation (Xue et al.,
2008), i.e., the creation of a propagating entity from soluble
protein, is an important contribution to the overall polymer-
ization reaction. For prion growth, however, this spontaneous
nucleation process is, in general, very slow, a fact which un-
derlies the capability of prion mediated inheritance in fungi
to function as a bistable switch (Shorter and Lindquist, 2005;
Wickner et al., 2007). The slow rate of nucleation (or the ef-
ficient clearance of seeds) is also implied by the low fre-
Figure 2. Fibril replication model. Nucleated polymerization
model as a basis for understanding prion growth. Monomers circle
are incorporated into growing fibrils in the elongated step 1 and
multiplication of active ends occurs through fragmentation 2. The
strain-dependent frangibility of aggregates leads to different propa-
gation rates: a mechanically robust strain A has a stable core and
fragments slowly, whereas a more frangible strain B multiplies faster
resulting in more efficient incorporation of cellular protein green
into the aggregates.
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quency of onset of sporadic versus transmitted mammalian
prion conditions (Aguzzi et al., 2007). Recent studies linking
expression levels of proteins in a cell with their intrinsic ag-
gregation propensity (Tartaglia et al., 2007) suggest that the
natural stability of proteins in their native soluble state is, in
general, guaranteed through kinetic, not thermodynamic,
barriers. This kinetic stability of soluble cellular prion pro-
teins is then perturbed by the presence of preformed aggre-
gates which accelerate the conversion to the prion isoform.
Within this framework, the ability of prions to proliferate in a
given environment is governed by nucleated polymerization
theories (see Fig. 2) defined through a set of rate constants
(Masel et al., 1999; Pöschel et al., 2003; Hall and Edskes,
2004; Carulla et al., 2005) for the different processes. In this
picture, growth—expressed by the elongation and division
rates—competes against the removal of prions through cel-
lular clearance mechanisms.
PHYSICAL AND STRUCTURAL DETERMINANTS
OF PRION STRAINS
The apparent simplicity in the elementary steps of prion
growth raises the question of how they can account for the
biological complexity encountered in prion biology and, in
particular, how they can generate the prion strain phenom-
ena. First hints at the answer came from the study of yeast
prions. It is increasingly apparent that the mechanical frangi-
bility (the propensity to break) of formed prion fibrils plays a
key role in this context (Tanaka et al., 2006). Yeast prions
have been shown to possess inherent frangibilities which dif-
fer substantially between strains but are relatively homoge-
neous within one class of fibrils belonging to a given strain
(Tanaka et al., 2006; Immel et al., 2007). For instance, some
of the stronger yeast prion strains have been found to be com-
posed of amyloid fibrils possessing the largest propensity to
fragment, thereby leading to a more aggressive tendency to
multiply in vivo. It is interesting to note that in terms of their
mechanical rigidity, amyloid fibrils can be very heteroge-
neous (Knowles et al., 2007) implying substantial potential
for intrinsic variability in their breakage rates. Although
prion propagation in mammalian tissues may inherently be a
more convoluted process, recent observations hint that a
similar kinetic description which has been validated for
fungi could be important for the propagation of mammalian
prion strains. Indeed, shorter fibrils such as those which
would result from breakage of frangible structures are more
infectious than longer fibrils (Silveira et al., 2005), a conclu-
sion which is consistent with the fact that a larger number of
free ends in a short fibril population leads to a more rapid
conversion of soluble cellular prion protein into misfolded
fibrillar form, thereby overwhelming and overcoming cellu-
lar clearance mechanisms. In addition, the chemical stability
and resistance to disaggregation by ex vivo amyloid material
is highly strain dependent (Safar et al., 1998), indicating that
differences in the robustness of the aggregates could charac-
terize the differential propagation of strains. In agreement
with this idea, an inverse correlation has recently been pro-
posed between the stability of the prion aggregate and their
incubation times in vivo (Legname et al., 2006), a finding
which is closely analogous to the corresponding results ob-
tained for yeast prions (Toyama et al., 2007; Tanaka et al.,
2004). It is frequently found that for in vitro growth assays of
many amyloid fibril systems agitation significantly enhances
the overall conversion rate of proteins into fibrillar form
(Sluzky et al., 1991; DePace et al., 1998; Serio et al., 2000;
Ohhashi et al., 2005; Atarashi et al., 2007; Kim et al., 2007),
an indication that modulations of fibril breakage are essential
factors determining the rate of amyloid formation in general.
In living systems, the rate constants for the multiplication of
prions are clearly influenced not only by the intrinsic strength
of the aggregates but also by other cellular components; mo-
lecular chaperones in yeast, for instance, have been identified
as vital actors in this context (DebBurman et al., 1997;
Shorter and Lindquist, 2004).
Taken together, the observations discussed above suggest
that differences in the kinetics of the elementary steps of
prion growth underlie the differential proliferation of prion
strains. In order to be successfully propagated, these differ-
ences have to stem from well-defined molecular level
changes in the structures of the insoluble prion aggregates
(Aguzzi, 2004). Concrete indications that this is indeed the
case have recently accumulated. Elegant studies using
hydrogen/deuterium exchange probed by solution NMR
(Toyama et al., 2007), fluorescence spectroscopy (Krishnan
and Lindquist, 2005), and x-ray crystallography (Sawaya et
al., 2007; Nelson et al., 2005) have recently highlighted
widespread structural polymorphism and identified some of
the characteristics differentiating prion strains. Emerging as
an important factor here is the size of the stabilizing cross-
amyloid core which appears to define the physical properties
of the resulting structures such as their propensity to frag-
ment, with small core sizes leading to enhanced frangibility.
Furthermore, covalent crosslinking of the precursor proteins
at well-defined locations to favor small or alternatively large
core sizes in the seed material is sufficient to result in the
production of a population of fibrils of the corresponding
strains (Krishnan and Lindquist, 2005). Indications of self-
propagating strain dependent conformational changes have
similarly been identified for three mammalian PrP amyloid
fibril systems (Jones and Surewicz, 2005). These fibrils,
when growing in cross-seeding experiments, adopt the struc-
tural features determined by the seed prion fibrils, even in
cases where this does not coincide with the preferred mor-
phology of the monomer when polymerized de novo. This
type of seed determined polymorphism is increasingly ap-
pearing as a generic feature of self-propagating amyloid
structures more generally. For instance A1–42 fibrils of
the type associated with Alzheimer’s disease have been
found to exist in two structurally and morphologically dis-
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tinct conformations which accurately propagate the
structure-encoded information to subsequent generations of
fibrils (Petkova et al., 2005). Interestingly, recent experi-
ments in transgenic mice created to develop -amyloid
plaques further suggest that the analogies between prions
and A aggregates could be broader than was initially sus-
pected. When these mice were injected with brain homoge-
nate containing A amyloid, a seeding effect was observed,
causing an accelerated deposition of A plaques. In addi-
tion, certain strain patterns, partially encoded by the injected
seeds, appeared to be observable suggesting that there are
still unexplored similarities between Alzheimer’s and prion
diseases (Meyer-Luehmann et al., 2006). Measurements by
atomic force microscopy of three nondisease related amyloid
systems has yielded indications that several, typically of the
order of 5–10, energetically close but structurally different
packings for polypeptide chains can exist within different
fibrils, and that subsequent monomer addition onto these
templates preserves the packing type (Knowles et al., 2006).
These numbers are interestingly of a similar order of magni-
tude to the numbers of prion strains identified ex vivo based
on their biochemical characteristics (Safar et al., 1998).
The intrinsic susceptibility towards polymorphic aggre-
gation is also increasingly appearing as a determining factor
in the species barrier phenomenon, which prevents certain
prion aggregates, but not others, from proliferating in a host
organism producing cellular prion protein with a different
sequence to that of the initial infectious seed material. For
instance, amyloid fibrils formed from a fragment of the
mammalian prion protein have been shown to have the fast-
est growth rates in vitro in cross-seeding experiments when
the preferred fibrillar structures of the growth protein and
seed protein are similar (Jones and Surewicz, 2005). In cases
where significant differences in fibril core structure were
identified by infrared spectroscopy and atomic force micros-
copy, the cross-seeding capacity was abolished. The primary
sequence of the prion protein appears therefore only to inter-
vene in the species barrier through the preferred fibril struc-
ture it confers. This preference for a given conformation of a
protein in the fibrillar state seems furthermore to stem pre-
dominantly from specific, in many cases short, portions of
the polypeptide sequence (Santoso et al., 2000; Tessier and
Lindquist, 2007). Yeast prion proteins which possess two
such “recognition elements” corresponding to two different
strains have consequently been shown to possess the ability
to fibrilize efficiently in the presence of seeds from either
strain (Tessier and Lindquist, 2007) whereas proteins with
only one such element can only grow into fibrils when
seeded with aggregates from the corresponding strain.
Finally, it is interesting to speculate that general mecha-
nisms given by the statistical physics of heterogeneous
chain-like molecules lie behind the widespread polymor-
phism of proteins in prion states, a feature which is generally
absent or less pronounced for native states where a given se-
quence encodes a unique three-dimensional conformation.
The energy landscape governing according to the “new
view” of protein folding (Frauenfelder et al., 1991; Dobson
et al., 1998) the reliable acquisition of native states of pro-
teins with given amino-acid sequences has been optimized
by evolutionary pressures to be smooth and free of frustra-
tion in order to avoid the situation where competing interac-
tions could trap the protein into local energy minima corre-
sponding to partially folded nonfunctional states (Dobson et
al., 1998; Dobson, 2003). However, prions and amyloid
structures more generally by their very nature circumvent the
normal folding funnel (Dobson, 2003), and are therefore
likely to experience a rougher energy landscape characteris-
tic of frustrated systems where interactions which cannot be
simultaneously satisfied lead to multiple distinct energy
minima. The connectivity imposed by the polypeptide back-
bone together with the requirement for a stable cross- core
hinders the independent search for an optimal chemical en-
vironment for the individual amino acids, for instance
through their differential positioning in the fibril core or al-
ternatively in solvent exposed parts outside of it. This type of
intrinsic frustration then implies that several distinct ar-
rangements which favor a certain subset of globally incom-
patible interactions are possible, reflecting for instance in the
observed strain-dependent differences in the parts of the se-
quence incorporated into the fibril core (Toyama et al.,
2007). In this sense the strain phenomenon can be seen to
follow naturally from the physical features of the protein
folding landscape when sampled outside of the range nor-
mally used by nature.
CONCLUSION
Although many similarities to other neurodegenerative pro-
tein misfolding diseases such as Alzheimer’s, Huntington’s,
and Parkinson’s disease have been described (DeArmond,
1993; Aguzzi and Haass, 2003), prion diseases were thought
to be unique in that they are transmissible and likely show
protein structure encoded strain properties. However, as an
acceleration of disease onset and certain strain properties ap-
pear to be encoded in experimentally transmitted A seeds,
it would appear that there are still unexplored similarities be-
tween Alzheimer’s and prion diseases to be discovered
(Meyer-Luehmann et al., 2006). Despite our increased un-
derstanding of the epidemiology and general biology of
prion diseases many key questions are still unanswered
(Table I). As new and more advanced techniques for studying
prion biology are being developed continuously, our hope
and belief is that some of these questions will be addressed
within the foreseeable future. New tools such as LCPs, solid
state nuclear magnetic resonance, advanced cell culture
models, including the cell panel assay or the prion organo-
typic slice culture assay (POSCA; prion replication in ex vivo
slices of living brain tissue) (Mahal et al., 2007; Falsig et al.,
2008) can hopefully help us address some of these important
HFSP Journal
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issues, including the structure of amyloids, the molecular ba-
sis underlying the prion strain phenomena and the cause of
neurodegeneration.
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